Significance of Aspergillus spp. isolation in defining cases of COVID-19 Associated Pulmonary Aspergillosis - CAPA

ABSTRACT COVID-19-Associated Pulmonary Aspergillosis (CAPA) is a relatively common complication in patients with severe forms of the disease caused by the SARS-CoV-2 virus. Diagnosing and confirming CAPA is challenging. In this study, Aspergillus spp. isolation in respiratory specimens from patients with COVID-19 was evaluated for identifying cases of CAPA. In 2020-2021, 17 Aspergillus spp. were isolated from 15 COVID-19 patients admitted to a university hospital in Brazil. Patient records were retrospectively reviewed to obtain clinical-epidemiological data and other markers of Aspergillus spp. infection and then compared with the ECMM/ISHAM criteria for defining CAPA. Probable CAPA was defined in 5/10 patients, who had Aspergillus spp. isolated from Bronchoalveolar Lavage (BAL) or a positive galactomannan blood test. Additionally, anti-Aspergillus antibodies were detected in two of these patients, during active or follow-up phases of CAPA. In another seven patients with Aspergillus spp. isolated from tracheobronchial aspirate or sputum, CAPA was presumed, mainly due to deterioration of clinical conditions and new lung imaging suggestive of fungal infection. Antifungal agents to control CAPA, particularly voriconazole, were used in 9/15 cases. In cases of probable CAPA and remaining patients, clinical conditions and comorbidities were similar, with lethality being high, at 60% and 71%, respectively. The number of CAPA cases defined by scientific criteria was lower than that assumed in the clinical context. This was largely due to the lack of BAL collection for fungal culture and the non-intensive use of other markers of invasive aspergillosis. The isolation of Aspergillus spp. in different respiratory specimens should alert clinicians to the diagnosis of CAPA.

Chromoblastomycosis in the amazon region, BRazil, caused by fonsecaea pedrosoi, fonsecaea nubica, and Rhinocladiella similis: clinicopathology, susceptibility, and molecular identification

Chromoblastomycosis is a chronic subcutaneous disease caused by human contact with melanized fungioccurring mainly in tropical and subtropical zones worldwide. This study assessed 12 patients with chro-moblastomycosis from Rondˆonia, Brazil, Amazon region. In sum, 83.3% were men, 41.6% were from MonteNegro city, median age was 52.9 years, and median time to disease progression was 12.2 years. Lesions werelocated on the lower limbs (75%), and verruciform was prevalent form (66.6%). After 3 years of treatmentwith itraconazole, two patients were considered cured. The etiological agents were identified by the molec-ular sequence of the ribosomal internal transcribed spacer ITS1, 5.8S, and ITS2 region andß-tubulin genes.Eight strains were identified asFonsecaea pedrosoi, two wereF. nubica,and two wereRhinocladiella similis.The antifungal activity of five drugs was evaluated, and the most active drug was terbinafine (range minimalinhibitory concentration [MIC] 0.015­0.12µg/ml), itraconazole (range MIC 0.03­0.5µg/ml) and voriconazole(range MIC 0.06­0.5µg/ml). The highest MIC was 5-fluorocytosine (range MIC 2­32µg/ml), and ampho-tericin B (range MIC 0.25­2µg/ml). In conclusion, the present study expanded the epidemiological diseasedatabase and described for the first timeF. nubicaandR. similisas chromoblastomycosis agents in theBrazilian Amazon region. Our results confirmed the importance of using molecular methods to identify themelanized fungi and stimulate the recognition of the disease in other places where no cases have beenreported.

Caracterização fenotípica e genotípica de cepas de Fonsecaea pedrosoi isoladas de pacientes com cromoblastomicose / Phenotypic and genotypic characterization of Fonsecaea pedrosoi strains isolated from patients with chromoblastomycosis

A cromoblastomicose é uma infecção subcutânea causada por fungos demácios, como a Fonsecaea pedrosoi. O pleomorfismo e a similaridade entre gêneros e espécies, ocorrências características dessa classe de fungos, podem interferir na identificação morfológica. Vários esquemas terapêuticos para o tratamento da cromoblastomicose já foram utilizados, mas até o momento não existe uma terapia padrão. Em alguns casos, a correta identificação do agente etiológico pode auxiliar na indicação terapêutica, pois algumas espécies respondem melhor a determinados tratamentos do que outras. Com o objetivo de auxiliar o diagnóstico laboratorial da cromoblastomicose, foi desenvolvido um teste para identificação molecular e detecção rápida da Fonsecaea pedrosoi, empregando-se a metodologia da PCR-duplex com iniciadores específicos para a F. pedrosoi e universais para fungos...